Diabetes mellitus

Reading File

Finding Sources

Searching PubMed

"diabetes mellitus" AND management

Finding Sources

Reading File

Loading Image

Reading File

Loading Image

Searching the Web

diabetes mellitus ADA 2025 2026 management guidelines updates

I now have extensive, authoritative content from Robbins and Harrison's 22e. Let me compile the comprehensive answer.

Diabetes Mellitus

Diabetes mellitus (DM) is a group of metabolic disorders sharing the common feature of hyperglycemia, caused by defects in insulin secretion, insulin action, or most commonly both. Chronic hyperglycemia produces secondary damage in the kidneys, eyes, nerves, and blood vessels. In the United States it is the leading cause of end-stage renal disease, adult-onset blindness, and non-traumatic lower-extremity amputations. - Robbins, Cotran & Kumar Pathologic Basis of Disease, p.1014

Epidemiology

30 million Americans (>11% of the population) have DM; ~1.9 million have Type 1
Nearly 25% of affected individuals are unaware of their diagnosis
~96 million US adults have prediabetes
~422 million people affected worldwide (WHO estimate)
T2D in adolescents has increased dramatically due to rising childhood obesity
Total yearly US cost: ~$327 billion ($237B direct medical + $90B indirect)

Pancreatic Islet Histology

The islets of Langerhans contain three main hormone-producing cell types, as shown below:

Pancreatic islet cell immunostaining: β cells (insulin), α cells (glucagon), δ cells (somatostatin), with electron micrographs of secretory granules

Immunoperoxidase staining of pancreatic islets showing β cells (insulin), α cells (glucagon), and δ cells (somatostatin), with electron micrographs of their distinct secretory granules. (Robbins, Fig. 24.27)

Diagnosis

Blood glucose is normally maintained at 70-120 mg/dL. ADA/WHO diagnostic criteria (any one of the following, confirmed on a separate day except for criterion 2):

Criterion	Value
Fasting plasma glucose	≥ 126 mg/dL
Random plasma glucose + classic symptoms	≥ 200 mg/dL
2-hr plasma glucose (75g OGTT)	≥ 200 mg/dL
HbA1c	≥ 6.5%

Prediabetes criteria (one or more):

Fasting glucose: 100-125 mg/dL ("impaired fasting glucose")
2-hr OGTT glucose: 140-199 mg/dL ("impaired glucose tolerance")
HbA1c: 5.7-6.4%

Up to one-quarter of individuals with impaired glucose tolerance will develop overt diabetes within 5 years. Even prediabetes carries significant cardiovascular risk. - Robbins, p.1015

Classification

Feature	Type 1 (T1D)	Type 2 (T2D)
Prevalence	~5-10% of DM	~90-95% of DM
Mechanism	Autoimmune β-cell destruction → absolute insulin deficiency	Insulin resistance + relative β-cell insufficiency
Age at onset	Usually <20 yrs (can be any age)	Classically adult-onset; now also in youth
Body habitus	Often lean	Usually overweight/obese
HLA association	Yes (HLA-DR3, DR4)	No
Autoantibodies	Yes (anti-GAD, anti-islet cell, anti-insulin)	No
Ketoacidosis risk	High	Low (but possible)

Other categories include: gestational DM, MODY (maturity-onset diabetes of the young), secondary DM (pancreatitis, Cushing syndrome, acromegaly, drugs), and rare monogenic forms.

Pathogenesis

Type 1 Diabetes

T1D involves failure of self-tolerance in T cells specific for islet antigens:

Autoreactive T cells escape thymic deletion (or regulatory T-cell suppression fails)
Initial activation occurs in peripancreatic lymph nodes in response to released islet antigens
Activated Th1 cells secrete IFN-γ and TNF → β-cell injury
CD8+ cytotoxic T lymphocytes directly kill β cells
Target autoantigens include insulin, GAD (glutamic acid decarboxylase), and others
Circulating autoantibodies are markers, not the primary effectors

Three stages of T1D (as recognized by JDRF/ADA):

Three-stage model of Type 1 diabetes progression showing declining β-cell mass over time

Robbins, Fig. 24.31 - The three stages of T1D, based on the JDRF/Endocrine Society/ADA scientific statement.

Stage 1: ≥2 islet autoantibodies present; normoglycemia; presymptomatic
Stage 2: Dysglycemia (impaired glucose tolerance) but still presymptomatic; 75% risk of symptomatic disease within 5 years
Stage 3: Classic symptomatic disease (polyuria, polydipsia, polyphagia, ketoacidosis) - occurs after >90% β-cell loss

Genetic factors: HLA-DR3 and HLA-DR4 confer the highest risk; monozygotic twin concordance is only ~50%, indicating environmental triggers (viral infections, molecular mimicry with islet antigens).

Type 2 Diabetes

Two central pathogenic defects:

Peripheral insulin resistance - especially in skeletal muscle, liver, adipose tissue
β-Cell dysfunction - relative insulin deficiency; β cells cannot compensate for insulin resistance

Obesity drives insulin resistance through:

Excess free fatty acids (FFAs)
Pro-inflammatory adipocytokines (e.g., TNF-α, IL-6, leptin, reduced adiponectin)
Chronic low-grade inflammation

The natural history of T2D: compensatory hyperinsulinemia → impaired glucose tolerance → progressive β-cell exhaustion → overt hyperglycemia.

Clinical Features (Symptoms of Hyperglycemia)

Per Harrison's 22e:

Polyuria (osmotic diuresis from glucosuria)
Polydipsia (secondary to polyuria)
Weight loss (caloric loss in urine + muscle catabolism)
Fatigue and weakness
Blurred vision (changes in lens water content - resolves with glycemic control)
Recurrent infections (vaginitis, fungal skin infections, UTIs)
Slow wound healing

T2D patients may be asymptomatic for years and present with established chronic complications at diagnosis.

Chronic Complications

Sustained hyperglycemia leads to long-term complications through four key biochemical mechanisms:

Mechanism	Effect
Advanced glycation end-products (AGEs)	Cross-link proteins, activate receptors → vascular damage
Protein kinase C (PKC) activation	Alters vascular permeability, gene expression
Polyol pathway disturbances	Sorbitol accumulation → osmotic injury (lens, nerves)
Hexosamine pathway overload	Alters gene transcription

Macrovascular (Macroangiopathy)

Atherosclerosis (accelerated) - coronary, cerebral, peripheral arteries
Ischemic heart disease (leading cause of death in DM)
Stroke
Peripheral artery disease → lower-extremity ischemia, gangrene, amputation
Women with DM have a sixfold greater risk of dying from CVD vs. non-diabetic women - Harrison's 22e, p.3209

Microvascular (Microangiopathy)

Diabetic retinopathy - leading cause of adult-onset blindness in the US
- Background (non-proliferative): microaneurysms, hard exudates, flame hemorrhages
- Proliferative: neovascularization → vitreous hemorrhage, retinal detachment
Diabetic nephropathy - leading cause of end-stage renal disease in the US
- Glomerular hyperfiltration → microalbuminuria → overt proteinuria → declining GFR
- Kimmelstiel-Wilson nodules (nodular glomerulosclerosis) pathognomonic
Diabetic neuropathy - most common long-term complication
- Distal symmetric polyneuropathy (glove-and-stocking)
- Autonomic neuropathy: gastroparesis, orthostatic hypotension, erectile dysfunction, cardiac denervation

Other Complications

Diabetic foot - combination of neuropathy + ischemia + infection
Increased susceptibility to infections (neutrophil dysfunction)
Skin: acanthosis nigricans, necrobiosis lipoidica, diabetic dermopathy

Acute Complications

Complication	Type	Mechanism	Key Features
DKA (Diabetic Ketoacidosis)	T1D (mainly)	Absolute insulin deficiency → lipolysis → ketogenesis	pH <7.3, bicarbonate <15, ketonemia, anion gap acidosis, fruity breath
HHS (Hyperosmolar Hyperglycemic State)	T2D (mainly)	Relative insulin deficiency, profound dehydration	Glucose often >600 mg/dL, serum osmolality >320 mOsm/kg, minimal ketosis
Hypoglycemia	Both	Excess insulin, missed meals, exercise	Glucose <70 mg/dL; sweating, tremor, confusion, seizure

Management Overview

Glycemic Targets (ADA)

HbA1c: <7.0% for most adults (individualized; <6.5% in select patients, <8.0% in elderly/high-risk)
Fasting glucose: 80-130 mg/dL
Post-prandial peak: <180 mg/dL

Non-Pharmacologic

Medical nutrition therapy (reduce refined carbohydrates, saturated fat; increase fiber)
Aerobic + resistance exercise ≥150 min/week
Weight loss (5-10% body weight improvement significantly improves T2D)
Smoking cessation
Sleep hygiene (poor sleep worsens insulin resistance)

Pharmacologic - T1D

Insulin therapy (mandatory): multiple daily injections or continuous subcutaneous infusion
- Basal insulin (glargine, detemir, degludec) + prandial insulin (lispro, aspart, glulisine)
Continuous glucose monitoring (CGM)
Adjunct agents: pramlintide, SGLT2 inhibitors (select patients)

Pharmacologic - T2D (Stepwise)

Drug Class	Example	Mechanism	Key Benefit
Biguanides	Metformin	Reduces hepatic glucose output	First-line; low cost; weight neutral
GLP-1 receptor agonists	Semaglutide, liraglutide	Enhance insulin secretion, suppress glucagon	Weight loss, CV benefit
SGLT2 inhibitors	Empagliflozin, dapagliflozin	Block renal glucose reabsorption	CV + renal protection
DPP-4 inhibitors	Sitagliptin	Increase GLP-1 activity	Weight neutral
Sulfonylureas	Glipizide, glimepiride	Stimulate insulin secretion	Low cost; hypoglycemia risk
Thiazolidinediones	Pioglitazone	Improve insulin sensitivity	Fluid retention risk
Insulin	Various	Replace deficient insulin	Use when oral agents insufficient

Current guidance (ADA/ESC): for T2D patients with established ASCVD or CKD, an SGLT2 inhibitor or GLP-1 RA should be added regardless of HbA1c level, given their proven cardiorenal protective effects (class I recommendation).

Monitoring and Screening

Per Harrison's 22e, p.3247-3248:

Annual dilated retinal exam (ophthalmologist)
Annual foot examination: pedal pulses, monofilament sensation (10-g), vibratory sensation (128-Hz tuning fork), ankle reflexes
Annual urine albumin-to-creatinine ratio + eGFR
Lipid profile at diagnosis and periodically
Blood pressure at every visit (target <130/80 mmHg)
Distal symmetric polyneuropathy screening: from diagnosis in T2D; 5 years after diagnosis in T1D

Special Considerations

Sex Differences (Harrison's 22e)

Women are more sensitive to insulin than men, yet prevalence of T2D is similar between sexes
Higher testosterone in women → increased T2D risk; lower testosterone in men → increased risk (confirmed by Mendelian randomization)
PCOS, gestational DM, preeclampsia → significantly elevated T2D risk
Women with DM lose the "female cardiovascular protection" - their CVD risk equals that of diabetic men

Gestational Diabetes (GDM)

Defined as glucose intolerance first recognized during pregnancy
Screened at 24-28 weeks gestation using 50g glucose challenge (then 100g OGTT if abnormal)
Increases risk of fetal macrosomia, neonatal hypoglycemia, operative delivery
Mother has high lifetime risk of developing T2D

Summary Pathology Points (Robbins)

T1D: Autoimmune β-cell destruction → absolute insulin deficiency. Circulating autoantibodies to islet antigens (including insulin and GAD). T-cell mediated.

T2D: No autoimmune basis. Insulin resistance + β-cell dysfunction → relative insulin deficiency. Obesity contributes through excess FFAs, pro-inflammatory adipocytokines, and inflammation.

Complications: Both types share identical late complications - macroangiopathy (atherosclerosis, IHD, PAD) and microangiopathy (retinopathy, nephropathy, neuropathy) - all driven by the four biochemical pathways of hyperglycemia-induced damage (AGEs, PKC, polyol, hexosamine).

Recent evidence note: A 2024 meta-analysis (PMID 39037772) confirmed that digital interventions for T2D self-management significantly improve glycemic outcomes. An ongoing meta-analysis (2025) identified GLP-1 receptor agonist GI adverse events as a clinically relevant safety signal (PMID 40499738), relevant to the rapidly expanding use of semaglutide and similar agents in T2D and obesity.

This is a shared conversation. Sign in to Orris to start your own chat.